Advertisement

prostate cancer

AR-V7 Assay Findings and Outcomes With Hormone Therapy in High-Risk Castration-Resistant Prostate Cancer

In the PROPHECY study, reported in the Journal of Clinical Oncology, Armstrong et al found that positive findings on 2 assays for circulating tumor cell (CTC) androgen receptor splice variant 7 (AR-V7) were associated with poorer outcomes for abiraterone and enzalutamide therapy in men with...

symptom management

Effect of Medical Cannabis on Symptom Control in Patients With Cancer

As reported in the Journal of Oncology Practice by Anderson et al, a study of patients enrolled in Minnesota’s Medical Cannabis Program showed that the use of medical cannabis was associated with improvement in reported symptoms in patients with cancer. The study involved data on 1,120...

breast cancer

Neratinib Plus Capecitabine Active Against HER2-Positive Breast Cancer Brain Metastases

In the phase II TBCRC 022 trial reported in the Journal of Clinical Oncology, Freedman et al found that the combination of neratinib and capecitabine was active against brain metastases in women with HER2-positive breast cancer. Modest activity of neratinib monotherapy had been found in previous...

gynecologic cancer

SGO 2019: Post Hoc Exploratory Analyses From the ARIEL3 Trial in Recurrent Ovarian Cancer

Data from post hoc exploratory analyses from the phase III ARIEL3 clinical study of rucaparib in recurrent ovarian cancer was presented during oral plenary and poster sessions at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer. These analyses...

gynecologic cancer
immunotherapy

SGO 2019: Dendritic Cell–Based Immunotherapy in Combination With Chemotherapy in Recurrent Ovarian Cancer

Results from a clinical trial presented by Cibula et al at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that a new immunotherapy treatment significantly prolongs survival in women with recurrent ovarian cancer when added to standard...

gynecologic cancer

SGO 2019: Treatment With Maintenance Niraparib in Recurrent Ovarian Cancer Extends Time Without Symptoms or Toxicity

Findings from a recent clinical trial presented in a Scientific Plenary session at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer revealed that women with recurrent ovarian cancer who received niraparib as maintenance therapy experienced more time...

gynecologic cancer
issues in oncology

SGO 2019: Brachytherapy Boost Added to EBRT and Chemotherapy in Advanced Cervical Cancer

A recent National Cancer Database study has shown the current standard of care for advanced cervical cancer—external-beam radiation and chemotherapy in combination with brachytherapy—provides significantly higher overall survival over chemoradiation alone. However, the addition of...

gynecologic cancer
issues in oncology

SGO 2019: HPV Vaccine Uptake in the Deep South

A study by Pierce et al presented at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that human papillomavirus (HPV) vaccination rates in Alabama are highest in counties with high incidence rates of HPV-related cancer (Abstract 13).  ...

lung cancer

FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer

On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer. IMpower133 Approval was based on the IMpower133 study, a...

prostate cancer

EAU 2019: Testosterone Replacement Therapy May Slow Recurrence in Low-Risk Prostate Cancer

Researchers have shown that testosterone replacement may slow the recurrence of prostate cancer in low-risk patients. Findings from the study were presented by Towe et al at the European Association of Urology (EAU) 2019 Congress (Abstract 646). Practitioners have long regarded testosterone as a...

bladder cancer

EAU 2019: Early Menopause in Smokers May Be Linked to Increased Risk of Bladder Cancer

New research has shown that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer; this higher risk was even more notable in smokers. The study, which looked at health outcomes in more than 220,000 patients, was presented by Abufaraj et al at the European...

issues in oncology
survivorship

Implementing Personalized Pathways for Cancer Follow-up Care in the United States

A new approach to cancer follow-up care is required to meet the needs of the growing population of cancer survivors in the United States, while also addressing provider shortages and rising costs, according to a new multiagency report. The report—published by Alfano et al in CA: A Cancer ...

breast cancer
colorectal cancer
lung cancer
pain management

Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers

In a linked Surveillance, Epidemiology, and End Results and Medicare study reported in the Journal of Clinical Oncology, Salz et al found that chronic opioid use varied by cancer among older cancer survivors. By 6 years after diagnosis, survivors were no more likely to be chronic opioid users...

issues in oncology

Strategies to Increase Inclusion of Racial and Ethnic Minorities in Clinical Trials

As reported in the Journal of Oncology Practice by Regnante et al, the National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group identified strategies employed by U.S. Cancer Centers of Excellence that have resulted in increased inclusion of racial ...

breast cancer

Use of Specialized PET/CT to Assess Estrogen Receptor Status in Recurrent or Metastatic Breast Cancer

In a Korean study reported in The Lancet Oncology, Chae et al found that 16α-[18F]fluoro-17β-oestradiol (18F-FES) positron-emission tomography/computed tomography (PET/CT) may permit accurate reevaluation of estrogen receptor status in recurrent or metastatic breast cancer when repeat...

breast cancer
leukemia
multiple myeloma
issues in oncology

FDA Pipeline: Assay Approval, Breakthrough Designations for AI Technology and CLL, and More

In the past week, the U.S. Food and Drug Administration (FDA) approved a companion diagnostic assay, granted Breakthrough Device and Breakthrough Therapy designations, and extended the review period of a proposed treatment. The agency also published four draft guidances and one final guidance...

skin cancer

Incidence of Nonmelanoma Skin Cancer in Recipients of Multiple Kidney Transplants

The incidence of nonmelanoma skin cancer may be more common in recipients of kidney transplants vs patients on maintenance dialysis. Researchers looked to determine if the risk of nonmelanoma skin cancer is lower during periods of graft loss with a return to dialysis vs during periods of...

cns cancers

Does Postoperative Conformal Radiotherapy Improve Survival in Pediatric Patients With Ependymoma?

Treatment with conformal radiation therapy immediately following surgery in children with ependymoma may greatly improve survival. The findings were published by Merchant et al in the Journal of Clinical Oncology. “Historically, children under the age of 3 with ependymoma have a worse...

prostate cancer
immunotherapy

Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Gulley et al found that PROSTVAC, a viral vector-based immunotherapy, did not improve overall survival or 6-month event-free survival vs placebo in patients with asymptomatic or minimally symptomatic metastatic castration-resistant...

kidney cancer

Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell Carcinoma

In a retrospective cohort study reported in The Lancet Oncology, Chanzá et al found evidence of activity of cabozantinib in advanced non–clear cell renal carcinoma. Cabozantinib is approved in metastatic renal cell carcinoma on the basis of studies in clear cell histology. As noted by ...

skin cancer

What Is the Best Field-Directed Treatment for Actinic Keratosis?

In a Dutch study reported in The New England Journal of Medicine, Jansen et al found that 5% fluorouracil cream was the best of four field-directed treatments for actinic keratosis, the most common premalignant skin disease in the white population. Study Details The study examined the...

issues in oncology
survivorship

Perceived Infertility Risk and Actual Fertility Status in Adult Survivors of Childhood Cancer

In a report from the St. Jude Lifetime Cohort Study in the Journal of Clinical Oncology, Lehmann et al found that perceptions of risk of infertility were often discordant with laboratory-assessed fertility status in adult survivors of childhood cancer. Study Details In the study, 1,067 survivors...

pancreatic cancer

Addition of Pegylated Recombinant Human Hyaluronidase to FOLFIRINOX in Metastatic Pancreatic Adenocarcinoma

In the phase I/II SWOG S1313 trial, which was reported in the Journal of Clinical Oncology by Ramanathan et al, researchers found that the addition of pegylated recombinant human hyaluronidase (PEGPH20) to modified (m) FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) worsened...

ASCO Honors Leaders in Cancer Care With 2019 Special Awards

ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...

issues in oncology
legislation

Statement on White House’s FY2020 Budget Proposal by ASCO President Monica M. Bertagnolli, MD, FACS, FASCO

ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, issued the following statement earlier this week: We strongly oppose the White House budget proposal for fiscal year (FY) 2020, which would stall our nation's progress against cancer and impede access to needed care for the millions of...

lung cancer

2019 Thoracic Cancers Symposium: Trends in Use of Prophylactic Cranial Irradiation for Extensive-Stage SCLC

A new survey of radiation oncologists points to a sharp decline in the use of prophylactic cranial irradiation for patients with extensive-stage small cell lung cancer (SCLC), indicating a rapid change in standard practice for the disease following the 2017 publication of a major clinical trial by...

lung cancer

2019 Thoracic Cancers Symposium: Effect of Structured Patient Exposure to the NCCN Guidelines for NSCLC

A new clinical trial found that exposing patients to tailored versions of the National Comprehensive Cancer Network (NCCN®) Guidelines for non–small cell lung cancer (NSCLC) may help drive smoking cessation, testing for potential biomarkers and, for early-stage disease, more...

lung cancer

2019 Thoracic Cancers Symposium: Local Consolidative Therapy and Overall Survival in Oligometastatic NSCLC

A new analysis of patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) found that the intensive treatment approach is associated with improved overall survival. Local consolidative therapy—consisting of radiation therapy or...

lung cancer
immunotherapy

Nivolumab Plus Ipilimumab in Advanced NSCLC: Outcomes by PD-L1 and Tumor Mutational Burden Status

As reported in the Journal of Clinical Oncology by Ready et al, the phase II CheckMate 568 trial has shown that higher tumor mutational burden is associated with response, irrespective of programmed cell death ligand 1 (PD-L1) expression in first-line nivolumab plus low-dose ipilimumab treatment of ...

health-care policy

HHS Secretary Appoints Norman E. Sharpless, MD, as FDA Acting Commissioner

Today, the Secretary of Health and Human Services (HHS) Alex M. Azar II appointed Norman E. Sharpless, MD, to be the acting Commissioner of the U.S. Food and Drug Administration (FDA). He will be replacing the current FDA Commissioner, Scott Gottlieb, MD, who announced his resignation on March 5....

breast cancer

Addition of Preoperative Breast MRI to Standard Evaluation in Local Ductal Carcinoma in Situ

In a French phase III trial reported in the Journal of Clinical Oncology, Balleyguier et al found that the addition of breast magnetic resonance imaging (MRI) to standard radiologic evaluation did not improve surgical reintervention rates in women with ductal carcinoma in situ undergoing...

breast cancer
gastroesophageal cancer
gastrointestinal cancer

FDA Approves Trastuzumab-qyyp in HER2-Overexpressing Breast and Gastric Cancers

The U.S. Food and Drug Administration (FDA) has approved trastuzumab-qyyp (Trazimera), a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...

issues in oncology

Lack of Genetic Diversity in Common Cancer Cell Lines

Researchers have found that some commercial cancer cell lines used for laboratory studies have mislabeled ancestry when it comes to minorities. These findings were published by Hooker et al in Cancer Epidemiology, Biomarkers & Prevention. “A lack of diversity is prevalent in every level...

issues in oncology
global cancer care

Global Incidence of Undiagnosed Pediatric Cancers

Nearly half of all childhood cancers are not being diagnosed globally, according to a new modeling study published by Ward et al in The Lancet Oncology. “Our model suggests that nearly one in two children with cancer are never diagnosed and may die untreated,” said lead...

prostate cancer

Intense Neoadjuvant Androgen Deprivation Before Prostatectomy in Locally Advanced Prostate Cancer

In a phase II trial reported in the Journal of Clinical Oncology, McKay et al found a trend toward improved pathologic response or minimal residual disease with the addition of neoadjuvant abiraterone and prednisone to enzalutamide and leuprolide prior to radical prostatectomy in patients with...

breast cancer
solid tumors
gynecologic cancer
lymphoma
survivorship

Subsequent Primary Neoplasms in Survivors of Adolescent and Young Adult Cancers

In a UK population-based cohort study (Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Bright et al found that subsequent primary neoplasms were most common in survivors of adolescent and young adult (AYA) breast, cervical, and testicular cancers, as well as Hodgkin...

skin cancer
immunotherapy

Safety Comparison of Two Dosing Regimens for Nivolumab Plus Ipilimumab in Advanced Melanoma

In the phase IIIb/IV CheckMate 511 study reported by Lebbé et al in the Journal of Clinical Oncology, a regimen of nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg (NIVO3+IPI1) was found to significantly reduce the incidence of treatment-related grade 3 to 5 adverse events compared with...

breast cancer
immunotherapy

FDA Grants Accelerated Approval to Atezolizumab/Nab-Paclitaxel; Regular Approval Contingent on Confirmatory Trials

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for the treatment of adults with unresectable, locally advanced or metastatic, programmed cell death ligand 1 (PD-L1)-positive ...

issues in oncology

Position Paper Addresses Shortages of Chemotherapy and Supportive Care Agents for Pediatric Oncology Patients

Shortages of essential chemotherapy drugs for children undergoing cancer treatment have been an increasingly frequent obstacle for patients and hospitals in the United States. These shortages can result in increased medication errors, delayed administration of life-saving therapy, inferior...

skin cancer

New Patient Resource: NCCN Guidelines for Patients With Squamous Cell Skin Cancer

The National Comprehensive Cancer Network® (NCCN) has published a new book of patient information that explains prevention, diagnosis, and treatment for squamous cell skin cancer. Squamous cell and basal cell skin cancers are responsible for about 5 million annual incidents of nonmelanoma...

breast cancer
issues in oncology
cost of care

Patients With Breast Cancer Provide Recommendations to Ease Financial Toxicity

A qualitative study yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services, and financial assistance to reduce long-term, breast cancer–related economic burden. The study was published by Dean et al in Cancer. Unique...

gynecologic cancer
issues in oncology
global cancer care

Modeling Study of Scaled-up HPV Vaccination and Cervical Cancer Screening

In a modeling study reported in The Lancet Oncology, Simms et al detailed the preventive effects on cervical cancer that could be achieved by scaled-up human papillomavirus (HPV) vaccination and cervical screening efforts with the aim of disease elimination. The major modeling projections are...

colorectal cancer

Combining Tumor Budding and Lymphocytic Infiltration May Improve Prognostic Accuracy in Colorectal Cancer

A study evaluating a prognostic signature derived from integrating tumor budding, lymphocyte infiltration, and their spatial relationship has found that the method could more accurately stratify patients with stage II colorectal cancer at high risk for disease-specific death compared with...

skin cancer

Is the Presence of Nevi on Extremities a Risk Factor for Melanoma and Nonmelanoma Skin Cancers?

The presence of nevi is an established risk factor for melanoma. In light of this, researchers examined the association between the presence of nevi on extremities and the risk of melanoma and nonmelanoma skin cancers. Their findings were published by Wei et al in the Journal of the American...

skin cancer
immunotherapy

A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma

A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be...

solid tumors
issues in oncology

Effect of Adjuvant Treatment for Early Testicular Cancer on Reproductive Potential

Men with early-stage testicular cancer can safely receive one course of adjuvant chemotherapy or radiotherapy without it having a long-term effect on their reproductive potential, according to a study published by Weibring et al in Annals of Oncology. Although it is known already that several...

leukemia

Effect of Hematopoietic Stem Cell Transplantation on Outcome in Pediatric Hypodiploid B-ALL

In a report from the Children’s Oncology Group (COG) in the Journal of Clinical Oncology, McNeer et al found that hematopoietic stem cell transplantation (HSCT) did not improve outcomes in pediatric patients with hypodiploid B-lymphoblastic leukemia (B-ALL). Study Details The study was a...

prostate cancer

Prevalence of Adverse Germline Genetic Variants in Prostate Cancer

In a study reported in JAMA Oncology by Nicolosi et al, it was found that 17% of men with prostate cancer had likely deleterious germline genetic variants, and that many of these men would not have been considered candidates for genetic testing. Study Details The study involved data from 3,607...

gynecologic cancer

Does Lymphadenectomy Improve Survival in Advanced Ovarian Cancer?

In the international phase III LION study reported in The New England Journal of Medicine, Harter et al found that lymphadenectomy did not improve progression-free or overall survival vs no lymphadenectomy in women with advanced ovarian cancer. Study Details The trial enrolled 647 women with...

FDA Commissioner Scott Gottlieb, MD, Resigns

On March 5, 2019, Scott Gottlieb, MD, announced his resignation as Commissioner of the U.S. Food and Drug Administration (FDA), a post he began in 2017. Dr. Gottlieb’s resignation will be effective next month. In a resignation letter to Alex M. Azar II, Secretary of Health and Human Services ...

Advertisement

Advertisement



Advertisement